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Abstract The liver endoplasmic reticulum glucose-6-phospha-
tase catalytic subunit (G6PC1) catalyses glucose 6-phosphate
hydrolysis during gluconeogenesis and glycogenolysis. The high-
est glucose-6-phosphatase activities are found in the liver and
the kidney; there have been many reports of glucose 6-phos-
phate hydrolysis in other tissues. We cloned a new G6Pase iso-
form (G6PC3) from human brain encoded by a six-exon gene
(chromosome 17q21). G6PC3 protein was able to hydrolyse
glucose 6-phosphate in transfected Chinese hamster ovary cells.
The optimal pH for glucose 6-phosphate hydrolysis was lower
and the Km higher relative to G6PC1. G6PC3 preferentially
hydrolyzed other substrates including pNPP and 2-deoxy-glu-
cose-6-phosphate compared to the liver enzyme.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The liver glucose-6-phosphatase catalytic subunit (G6PC1;
EC 3.1.3.9) is part of a multi-component system, located
mainly with its catalytic site oriented towards the lumen of
the endoplasmic reticulum in liver and kidney cells [1^3]. Two
proteins of the liver system have been cloned: the catalytic
subunit [4] and a glucose-6-phosphate transporter [5,6]. Ge-
netic de¢ciencies of any of the protein components of the
glucose-6-phosphatase system are classi¢ed as glycogen stor-
age disease type 1 (GSD) [3]. In liver, G6PC1 system catalyses
hydrolysis of glucose-6-phosphate into glucose and phosphate
and plays a critical role in blood glucose homeostasis [1^
3,7,8]. Glucose-6-phosphatase activity has also been detected
in the nuclear envelope [9], and in tissues other than liver
[1,2,10^12], this would suggest that its enzymatic activity
might also be used for other purposes such as locally regen-
erating glucose stocks or ATP levels [13].
Kinetic analysis of G6P transport in brain and liver sug-
gested that a di¡erent isoform of glucose-6-phosphate trans-
locase (G6PT1) transport protein might be present in brain
[14]. It was subsequently shown that a larger isoform of the
protein was present in brain arising from di¡erential splicing
of the G6PT1 gene. The Km of G6Pase catalytic subunit ac-
tivity is also not the same in all tissues raising the possibility
that there could be a di¡erent isoform of G6PC in non-hepat-
ic tissues [15].
An islet-speci¢c cDNA [16] (termed here G6PC2) was iso-
lated in 1999, it was a di¡erent gene product [17,18] which
potentially encodes a similar protein to G6PC1. The signi¢-
cance of the G6PC2 protein remains unclear as it was re-
ported to be inactive [16^18].
In the present work we cloned and expressed a third cDNA
(G6PC3) from brain RNA with sequence similarity to G6PC1.
We also characterised its enzymatic activity and compared it
to that of the liver G6PC1.
2. Materials and methods
2.1. Materials
Primers were synthesised by Genosys Biotech. The M-MLV reverse
transcriptase, oligod(T) primer, RNasin and pGEM-T cloning kit
were from Promega. Human brain RNA was from Ambion Inc.;
pcDNA 3.1+ vector was from Invitrogen. 2-Deoxy-glucose-6-phos-
phate (sodium salt, 2-deoxy-G6P), Mannose-6-phosphate (sodium
salt), Histone IIAS and cacodylic acid were from Sigma. Para-nitro-
phenyl phosphate (sodium salt, pNPP) was from ICN. Glucose-6-
phosphate (sodium salt) and all other chemicals were from Merck.
Human G6PC3 clone was kindly provided by the IMAGE consortium
(Cambridge, UK).
2.2. Methods
2.2.1. Reverse transcription-polymerase chain reaction (RT-
PCR). RNA was isolated by the TRIZOL procedure (Gibco) or
SV total RNA isolation (Promega). Total human brain RNA (1 Wg)
or Chinese hamster ovary (CHO) cell RNA (6 Wg) were reverse tran-
scribed according to the manufacturer’s instructions (oligod(T)15
primer for human RNA, random hexamers for CHO cells RNA)
using M-MLV reverse transcriptase, RNase H minus. Sense (5P-
ACTCTGGTTTCCGCCCTGGAGCAA-3P) and antisense (5P-CTG-
GAGTGTGGTGGTCACAGAGT-3P) primers were used for human
RNA and sense (5P-AGATATCCAGCACAGTGGCGGC-3P) and
antisense (5P-TGTGGGAGGGAAAGGAAAGGGA-3P) primers
were used for CHO cell RNA. PCR products were puri¢ed using
Wizard PCR preparation kit (Promega) then incubated with 10 mM
dATP and 2.5 U Taq polymerase (MBI Fermentas) at 72‡C for 1 h.
The DNA was repuri¢ed, ligated into pGEM-T vector and used to
transform XL1 Blue cells. Colonies were grown in LB-Amp and plas-
mid DNA puri¢ed using a Wizard miniprep kit (Promega).
2.2.2. Construction of expression vector. RT-PCR using adult hu-
man brain RNA was prepared as described above. The 1160 bp
cDNA was reampli¢ed using sense (5P-ATTACTCTCGAGTTT-
CCGCCCTGGA-3P) and antisense (5P-TGATTCTAGAGTGTGG-
TGGTCACA-3P) primers containing XhoI and XbaI restriction sites
0014-5793 / 03 / $22.00 N 2003 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0014-5793(03)00903-7
*Corresponding author. Fax: (44)-1382-632597.
E-mail address: a.burchell@dundee.ac.uk (A. Burchell).
Abbreviations: CHO, Chinese hamster ovary cell line; G6PC, cata-
lytic subunit of glucose-6-phosphatase; G6PT, glucose-6-phosphate
translocase; pNPP, para-nitrophenyl phosphate
FEBS 27591 27-8-03
FEBS 27591 FEBS Letters 551 (2003) 159^164
respectively (underlined sequences). PCR was prepared in a ¢nal vol-
ume of 25 Wl. PCR programme was performed as follows: 1 cycle:
95‡C (5 min); 30 cycles: 95‡C (1 min), 63‡C (1 min), 72‡C (2 min) and
last cycle: 72‡C (8 min). The PCR product was analysed on a 1%
agarose gel, extracted and digested with XhoI and XbaI restriction
enzymes, as pcDNA 3.1+ vector. After dephosphorylation of the
opened vector, the digested PCR product was ligated into it. XL1
Blue cells were transformed by electroporation. Colonies were grown
up and plasmid DNA was puri¢ed using a QIAgen plasmid maxi kit
(QIAgen). DNA was sequenced on an Applied Biosystem automated
DNA sequencer.
2.2.3. Cell culture and stable transfection. The CHO-K1 cells, ep-
ithelial cells from Chinese hamster ovary, were transfected with
G6PC3-pcDNA 3.1 using the lipofectin reagent (GibcoBRL) accord-
ing to the manufacturer’s instructions. Forty-eight transfected colo-
nies were obtained.
2.2.4. Northern blots. Total RNA (16 Wg) was separated on a
1.0% formaldehyde-agarose gel and transferred to nitrocellulose mem-
branes (Sigma). The membranes or the Clontech ‘Multiple Human
Tissue Northern Blot’ were hybridised overnight with appropriate
[32P]-labelled probes.
2.2.5. Preparation of rat liver microsomes. Microsomes were iso-
lated from Sprague Dawley rat livers as described elsewhere [19].
Microsomes were resuspended in a 0.25 M sucrose, 5 mM HEPES
bu¡er, pH 7.4, quickly frozen, and kept at 380‡C until use.
2.2.6. Preparation of cells for enzymatic assay. Con£uent cells
grown in 75 cm3 £asks were harvested by scraping and resuspended
in 5 mM HEPES, pH 7.4, centrifuged at 10 000Ug for 10 s and
resuspended in 600 Wl of ice-cold HEPES bu¡er. The suspension
was homogenised mechanically by hand with a glass/glass homoge-
niser and used immediately.
2.2.7. Assays. Glucose-6-phosphatase activity was measured using
a 96-well microplate assay derived from the colorimetric technique
previously described [20] using various concentrations of G6P and
other substrates. In some assays 1 mg/ml histone IIA [21] was used
to permeabilise microsomal vesicles [22]. Microsomal intactness was
measured and corrected for using mannose-6-phosphate [20,23]. In-
tactness was greater than 94% in all rat liver microsomal preparations.
Km and Vmax were determined by non-linear regression analysis [24].
All experiments were repeated at least three times. Protein concentra-
tions were determined as in [25]. All statistical calculations were car-
ried out using an unpaired t-test with two-tail P value (Prism com-
puter programme for Macintosh).
3. Results and discussion
Glucose-6-phosphatase activity has been reported in many
tissues especially during foetal development [1,2]. Kinetic pa-
rameters measured in some of these tissues, e.g. [16], di¡er
from those in liver and indicate that another G6PC protein
might exist in a number of non-hepatic tissues. Patients with
type 1a GSD (G6PC1 de¢ciency) have glycogen accumulation
in liver and kidney and symptoms associated with lack of
glucose production by the liver (and to a lesser extent the
kidney) [3]. Patients su¡er from episodes of fasting hypogly-
caemia after birth [3] but there is no evidence that there are
problems in utero [3] raising the possibility that there might be
another G6PC gene. More recently G6PC2 cDNA was iso-
lated from islets, it encodes a similar protein to G6PC1 [16].
However, G6PC2 mRNA seems to be islet speci¢c [16^18] and
therefore cannot account for glucose-6-phosphatase activity in
other tissues. We therefore looked for the presence of another
G6PC isoform in non-hepatic tissues.
3.1. Cloning and analysis of the new phosphatase sequence
The GenBank EST database contains a cDNA clone (ac-
cession number AA232171) isolated from human brain RNA
that has a length of about 1.3 kbp. This sequence contains an
ORF and we named it G6PC3 because of its similarity to both
liver G6PC1 [4] and G6PC2 [16]. Oligonucleotides designed
from the EST sequence were used to perform RT-PCR on
human brain mRNA. A single PCR product was obtained
with an apparent size of 1.1 kbp, it was cloned into a
pGEM-T vector, subcloned into pcDNA 3.1, and sequenced
in both directions. The nucleotide sequence was strictly iden-
tical to the AA232171 sequence. A BLAST search of the
NCBI nr database using the obtained sequence identi¢ed
two further clones: accession numbers BC002494 and
BC021574. These two clones and our PCR product showed
that the predicted G6PC3 initiation codon is located in the
context of a strong Kozak concensus sequence [26]. A BLAT
search of the UCSC Genome Bioinformatics database (http://
genome.ucsc.edu) allowed us to compare the G6PC3 sequence
and human genomic sequences in order to determine the num-
ber of exons/introns and their boundaries (Fig. 1). The
Fig. 1. Organisation of the G6PC3 gene and splicing of its tran-
script.
Table 1
Comparison of the kinetic parameters of the glucose-6-phosphatase activity in rat liver microsomes and in G6PC3-transfected CHO cells
Km (mM) Vmax (nmol/min/mg)
pH 5.5 pH 6.5 P pH 5.5 pH 6.5 P
Not disrupted
Liver 5.1U 0.7 1.3U 0.1* 0.0046 284U 19 294U 15 NS
G6PC3 4.1U 0.5 4.3U 0.4 NS 15.6U 1.6 18.3U 2.3 NS
Disrupted
Liver 0.5U 0.04** 0.3U 0.01*** 0.0054 495U 15 545U 3.8 0.0318
G6PC3 1.0U 0.06 2.0U 0.1 6 0.0001 36.5U 3.9 31.5U 2.4 NS
Each assay mixture contained 125 mM cacodylate pH 5.5 or 6.5, 2.5 mM EDTA, and various concentrations of G6P (1^10 mM). P values in
the table are pH 5.5 compared to respective values at pH 6.5. NS, not signi¢cant. *P=0.0012 compared to G6PC3 (not disrupted) Km at pH
6.5; **P=0.0035 compared to G6PC3 (disrupted) Km at pH 5.5; ***P6 0.0001 compared to G6PC3 (disrupted) Km at pH 6.5. G6PC3 activity
values were calculated removing the basal glucose-6-phosphate hydrolysis found in CHO cells from the values obtained using G6PC3-trans-
fected CHO cells. Control CHO cells transfected with empty pcDNA 3.1 vector had basal levels of glucose-6-phosphate hydrolysis which were
not signi¢cantly di¡erent from hydrolysis levels in normal CHO cells (data not shown).
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G6PC3 cDNA maps chromosome 17q21, as does G6PC1 [27].
It contains six exons (Fig. 1) and the cDNA (1041 bp) encodes
a hydrophobic protein of 346 amino acids (Fig. 2) with pre-
dicted Mw and pI of 38 734 and 8.47, respectively.
3.2. Comparison of expression of G6PC1 and G6PC3 mRNA
in human tissues
It has been known for many years that G6PC1 protein is
predominately expressed in gluconeogenic tissues, i.e. the liver
and to a lesser extent the kidney. Here we con¢rm that human
G6PC1 mRNA has the same expression pattern (Fig. 3). In
complete contrast G6PC3 mRNA levels are low in liver, and
relatively high in brain, heart, skeletal muscle, placenta and
kidney (Fig. 3). The tissues which express high levels of
G6PC3, with the exception of kidney (which also has high
levels of G6PC1), are not normally considered to be gluco-
neogenic tissues. These patterns of mRNA expression strongly
suggest that the glucose-6-phosphate hydrolysis activities pre-
viously found in a variety of non-hepatic tissues [1,2,10^
12,14,15], including brain and skeletal muscle, may be cata-
lysed by G6PC3 rather than G6PC1.
3.3. Structure predictions of G6PC3
Structure predictions were performed using Internet resour-
ces (http://www.ch.embnet.org/software/TMPRED_form.
html) for both human G6PC1 and G6PC3. The structure
prediction of the G6PC1 (Fig. 2) corresponds to the one pre-
viously described [28]. The predicted structure of the two
types of proteins (Fig. 2) is very similar with nine membrane
spanning segments. It must be stressed that in contrast to
G6PC1 and G6PC2, G6PC3 does not contain a C-terminus
(KK) endoplasmic reticulum transmembrane retention signal
[29] although not all endoplasmic reticulum transmembrane
proteins have the KK retention signal [29]. The regions of the
proteins that are thought to be part of the active sites
[28,30,31] are very conserved between the two sequences: a
conserved phosphatase sequence motif KXXXXXXRP-
(X1254)-PSGH-(X3154)-SRXXXXXHXXXQ/D is present in
the G6PC3 sequence (Fig. 4). The three most important cata-
lytic residues correspond to those of G6PC1, with Arg79 of
G6PC3 aligned to Arg83 of G6PC1, His114 to His119, and
His167 to His176. Furthermore, these predictions suggest that
these amino acid residues are located on the same side of the
Fig. 2. The predicted membrane topology of both human G6PC1 and G6PC3 proteins. Structural predictions for both human G6PC1 and
G6PC3 were performed using internet resources (http://www.ch.embnet.org/software/TMPRED_form.html). Strictly conserved amino acids are
in black and partially conserved residues in grey.
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membrane (Fig. 2), indicating the presence of a putative func-
tional active site. All 48 amino acids changes reported in
G6PC1 in cases of GSD type 1a [32] are shown in Fig. 4:
31 are strictly conserved in G6PC3, 10 are partially conserved
in G6PC3 and only seven of these amino acids di¡er in
G6PC3 (Q54s S50, G68sT64, G122s I117, W156s S147,
G222s I213, L265s S255, S298sC286). This conservation
of key amino acids suggests G6PC3 might be catalytically
active.
3.4. Enzymatic activities
CHO cells were therefore stably transfected with a plasmid
containing G6PC3. A clone in which Northern blot analysis
revealed relatively high levels of G6PC3 was chosen for the
study of G6PC3 function (Fig. 5). Glucose-6-phosphate hy-
drolysis occurred in the transfected cells in both untreated
(Fig. 6A) and disrupted vesicles (Fig. 6B). In disrupted
vesicles the values are a direct measurement of G6PC3 activity
[21,22]. In intact vesicles there is latency (Table 1) due to the
need to transport glucose-6-phosphate across a membrane
[1,3,19,20]. The presence of some activity with glucose-6-phos-
phate as substrate in intact vesicles together with the relative
di¡erences in substrate speci¢city between untreated and dis-
rupted vesicles indicates that a glucose-6-phosphate transport-
er and possibly other substrate transporter are present in
Fig. 3. Comparison of G6PC1 and G6PC3 expression in human tis-
sues RNA blotting analysis was performed using Clontech MTN
with 1 Wg of poly(A) mRNA in each lane of the blot. The hybrid-
isation was carried out sequentially on the same membrane using an
internal G6PC1 cDNA sequence of 646 bp covering exon 2 to exon
5 and an internal G6PC3 cDNA from exon 2 to exon 5 (677 bp) as
[32P]-labelled probes.
Fig. 4. Alignment of the deduced peptides sequences of the G6PC3 and G6PC1. Identities are indicated by black dots and similarities by verti-
cal bars. Residues de¢ned as being of key catalytic importance in phosphatases are shaded grey. Inactivating point mutations that abolish or
reduce G6Pase catalytic subunit and give rise to GSD type 1a are shown in single letter code above the G6PC3 sequence.
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CHO cell membrane vesicles. The possibility that low levels of
G6PT1 are present cannot be ruled out but it seems more
likely that the transport of glucose-6-phosphate is via the
recently described less speci¢c hexose phosphate transporter
recently found in cells lines and ¢broblasts from G6PT1 de¢-
cient patients with GSD 1b [33].
Levels of enzymatic activity in transfected CHO cells were
lower than in rat liver microsomes. This obviously re£ects the
levels of transfection but it is also consistent with the levels of
glucose-6-phosphatase activity in human non-hepatic and foe-
tal tissues that can be 10 times lower than in liver [12,15]. Rat
liver microsomes were chosen as a source of G6PC1 activity
rather than human liver microsomes for ethical reasons. Pre-
viously G6PC1 activity in adult rat and human liver micro-
somes have been shown to have the same Km and substrate
speci¢city, e.g. [3,20]. The pH optima for G6PC3 enzymatic
activity in disrupted vesicles is lower than that of G6PC1 (Fig.
6B), (approx. pHopt 6.5 as previously shown [34]). Km values
of glucose-6-phosphate hydrolysis by G6PC3 and liver G6PC1
in conditions where vesicles are not disrupted are similar at
pH 5.5 but di¡erent at pH 6.5 (Table 1). In disrupted con-
ditions, all Km values are lower for both isoforms at both
Fig. 5. Analysis of human G6PC3 presence by RNA blotting. Both
lanes were loaded with 16 Wg total RNA from transfected or non-
transfected CHO cells. The hybridisation was carried out using an
internal L actin cDNA (424 bp) and an internal G6PC3 cDNA
from exon 2 to exon 5 (677 bp) as [32P]-labelled probes.
Fig. 6. pH pro¢les of glucose-6-phosphatase activities in absence
(A) or presence of histone (B). Assays mixtures contained 125 mM
histidine (O, R) or cacodylate (a, b), 2.5 mM EDTA, 10 mM glu-
cose-6-phosphate. The actual pH of the mixtures was determined
under assay conditions. The enzymatic activities of G6PC3 (R, b,
left Y axis) were calculated by removing the basal enzymatic activ-
ities found in untransfected CHO cells from the values obtained us-
ing G6PC3-transfected CHO cells. CHO cells transfected with empty
pcDNA 3.1 vector had basal levels of glucose-6-phosphate hydroly-
sis which were not signi¢cantly di¡erent from levels in normal CHO
cells (data not shown). The activity scale of rat liver microsomes
(O, a) is represented on the right Y axis. The results represent the
mean of at least three di¡erent assaysU S.E.M.
Fig. 7. Enzymatic activities using di¡erent substrates in absence (A)
or presence of histone (B). Liver microsomal activity (open bars).
G6PC3 activity values (shaded bars) were calculated removing the
basal enzymatic activities found in CHO cells from the values ob-
tained using G6PC3-transfected CHO cell solution. Each mixture
contained 125 mM cacodylate pH 5.5 or 6.5, 2.5 mM EDTA, and
10 mM of substrate (pNPP, 2-deoxy-G6P, G6P) or 1 mM of M6P
(for intactness calculation). Each rate of substrate hydrolysis is rela-
tive to G6P hydrolysis (100%) for a given condition. The results
represent the mean of at least three di¡erent assaysUS.E.M.
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pH’s (Table 1). The Km values for disrupted liver microsomes
(Table 1) indicate a better a⁄nity for glucose-6-phosphate at
pH 6.5 for G6PC1 and pH 5.5 for G6PC3. This con¢rms that
G6PC3 is a glucose-6-phosphatase enzyme, with a di¡erent
Km to G6PC1 in our experimental conditions. While our
work was in progress, another similar sequence to G6PC1
and G6PC2 was identi¢ed and cloned from human melanotic
melanoma [35]. It has an identical sequence to G6PC3. It was
termed ubiquitously expressed G6Pase catalytic subunit-re-
lated protein as the authors failed to detect any enzymatic
activity of transiently expressed constructs in COS cells. It is
not clear why the authors [35] failed to detect any enzymatic
activity. The obvious di¡erences are (a) that a di¡erent cell
line was used and (b) that transient transfection experiments
were done in [35] and in contrast here we cloned cells that
stably express relatively high levels of G6PC3.
3.5. Substrate speci¢city
Liver G6PC1 is a relatively non-speci¢c phosphohydrolase.
We therefore used two other potential G6PC3 substrates to
determine if the two isoforms have the same relative substrate
speci¢cities. Assays were performed at pH 5.5 and 6.5 and
normalised to respective rates of glucose-6-phosphate hydro-
lysis (Fig. 7). pNPP, a classical substrate for many phospha-
tases, is rapidly hydrolysed by G6PC3 compared to glucose-6-
phosphate in both disrupted and non-disrupted conditions
(Fig. 7). In contrast to G6PC1, 2-deoxy-G6P is also a better
substrate than glucose-6-phosphate for G6PC3.
The fact that G6PC3 hydrolyses glucose-6-phosphate is log-
ical based on its sequence similarities to G6PC1 and its con-
served consensus phosphatase sequences. However, glucose
6-phosphate is not its preferred substrate in vitro (Fig. 7)
raising the possibility that glucose-6-phosphate might not be
the only substrate of G6PC3 in vivo. The role of G6PC3 in
brain and other tissues is not yet clear but one logical possi-
bility is that it supplies glucose for local use, i.e. for other cell
types in the same tissue.
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